GWS
ENTA icon

Glassman Wealth Services’s Enanta Pharmaceuticals ENTA Stock Holding History

Glassman Wealth Services’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-67
Closed -$630 – 710
2023
Q4 		$630 Sell
67
-36
-35% -$335 ﹤0.01% 1669
2023
Q3 		$1.15K Buy
+103
New +$1.66K ﹤0.01% 1510
2022
Q2 		– Sell
-5
Closed – – 1759
2022
Q1 		$0 Hold
5
– – ﹤0.01% 1722
2021
Q4 		$0 Hold
5
– – ﹤0.01% 1705
2021
Q3 		$0 Buy
+5
New +$247 ﹤0.01% 1651
2017
Q2 		– Sell
-3,083
Closed -$95K – 575
2017
Q1 		$95K Sell
3,083
-3,580
-54% -$111K 0.07% 119
2016
Q4 		$223K Buy
+6,663
New +$191K 0.16% 70
2016
Q2 		– Sell
-3,580
Closed -$105K – 434
2016
Q1 		$105K Hold
3,580
– – 0.1% 104
2015
Q4 		$118K Sell
3,580
-1,308
-27% -$42.6K 0.11% 104
2015
Q3 		$177K Hold
4,888
– – 0.16% 76
2015
Q2 		$220K Hold
4,888
– – 0.18% 61
2015
Q1 		$150K Buy
+4,888
New +$190K 0.12% 85

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Glassman Wealth Services's ENTA Position: Q1 2024 in Review

Glassman Wealth Services sold out of Enanta Pharmaceuticals (ENTA) in Q1 2024, closing a stake of 67 shares — an estimated $630 sold.

Glassman Wealth Services first reported a position in ENTA in Q1 2015 and held it in 12 quarters. The position peaked at $223K in Q4 2016. 108 funds tracked by Wall St. Rank hold ENTA as of Q1 2024.

  • Glassman Wealth Services reported no remaining Enanta Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 67 Enanta Pharmaceuticals shares in Q1 2024, an estimated $630.
  • Glassman Wealth Services first reported a position in Enanta Pharmaceuticals in Q1 2015 and held it in 12 quarters.
  • Glassman Wealth Services's Enanta Pharmaceuticals position peaked at $223K in Q4 2016.
  • 108 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.